Following retirement, Akoya Biosciences picks Silicon Valley executive as new CFO
PHOTO | Courtesy of Akoya Biosciences
Akoya Biosciences' fusion system instrument
Marlborough firm Akoya Biosciences named Johnny Ek to replace Joe Driscoll as the firm’s CFO, becoming the second new member of the company’s C-suite this year, after Jennifer Kamocsay was picked as general counsel.
Driscoll had overseen the company’s financials since 2019, including when it went public in 2021. He retired from the position on Monday.
Ek was previously CFO of San Jose-based Specific Diagnostics, and held the same role at GenMark Diagnostics in Carlsbad, California. Driscoll will continue at Akoya as a consultant throughout the transition, according to a Monday press release from the company.
“I deeply value the opportunity I’ve had at Akoya to build a strong organization and support the company’s incredible trajectory over the last four years. The company has established a strong foundation for continued high growth, and I look forward to supporting the transition of responsibilities to Johnny as Akoya enters its next phase of growth,” Driscoll said in the press release.
Akoya announced in February the appointment of Jennifer Kamocsay as its new general counsel. Kamocsay was previously in the same position at Rubius Therapeutics in Cambridge. In her role at Akoya, she will provide strategic guidance aid in the establishment of new partnerships, according to a Feb. 28 release from the company.
The company is led by CEO Brian McKelligon, who has been with the company since 2017.
WBJ Web Partners
Most Recent
Most Recent
0 Comments